4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Age Related Macular Degeneration by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 653 ongoing clinical trials involving Age Related Macular Degeneration
Of the 653 trials,336 trials are in Phase III
Furthermore, 120 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Age Related Macular Degeneration by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Age Related Macular Degeneration, an Ophthalmology Indication. Asia-Pacific boasts of the highest number of ongoing clinical trials involving Age Related Macular Degeneration. North America and Europe are among some of the other prominent regions involved in Age Related Macular Degeneration-related drug trials.

Novartis AG: The leading ongoing Age Related Macular Degeneration-related clinical trials sponsor

Novartis AG, a Switzerland-based pharmaceutical company, is the top sponsor for Age Related Macular Degeneration-related ongoing clinical trials.

F. Hoffmann-La Roche Ltd, Bayer AG, RegenxBio Inc, National Eye Institute, and Isarna Therapeutics GmbH are a few other notable sponsors involving Age Related Macular Degeneration.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Age Related Macular Degeneration

Aflibercept (Eylea, Eylia, Wetlia), Ranibizumab (Lucentis, Patizra), and Brolucizumab (Beovu, Vsiqq, Vizcu, Pagenax) are among the key marketed drugs involving Age Related Macular Degeneration.

Aflibercept (Eylea, Eylia, Wetlia), a Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Inhibitor, Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor, is indicated for the treatment of neovascular (wet) age-related macular degeneration (wet AMD) and for the treatment of macular edema following central retinal vein occlusion. It is also indicated for diabetic macular edema (DME) and Diabetic Retinopathy (DR) in Patients with DME. The drug is marketed globally including the United States, Australia, France, Germany, and Japan by Regeneron Pharmaceuticals Inc. Aflibercept was first approved in 2011 and formulated as an iso-osmotic injection solution for intravitreal route of administration.

Ranibizumab (Lucentis, Patizra), a Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor, is indicated for the treatment of patients with neovascular (Wet) age-related macular degeneration, macular edema following retinal vein occlusion (RVO) and diabetic macular edema. The drug is marketed globally including the United States, Australia, France, Germany, and Japan by Genentech USA Inc. Ranibizumab was first approved in 2006 and formulated as an injection for ophthalmic intravitreal use.